Expression and biological characterization of an anti-CD20 biosimilar candidate antibody-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Expression and biological characterization of an anti-CD20 biosimilar candidate antibody

Published:2012-07 Issue:4 Volume:4 Page:488-496
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Dorvignit Denise,Palacios Julio L.,Merino Maylin,Hernández Tays,Sosa Katya,Casacó Angel,López-Requena Alejandro,Mateo de Acosta Cristina

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.4161/mabs.20761

Reference38 articles.

1. Cd20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes

2. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience

3. B lymphocytes in systemic lupus erythematosus: lessons from therapy targeting B cells

4. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20

5. Complement-Induced Cell Death by Rituximab Depends on CD20 Expression Level and Acts Complementary to Antibody-Dependent Cellular Cytotoxicity

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potent immunomodulatory and antitumor effect of anti-CD20-IL2no-alpha tri-functional immunocytokine for cancer therapy;Frontiers in Immunology;2022-12-09

2. Assessment of Functional Characterization and Comparability of Biotherapeutics: a Review;The AAPS Journal;2021-12-20

3. The Dual Role of a Polyvalent IgM/IgA-Enriched Immunoglobulin Preparation in Activating and Inhibiting the Complement System;Biomedicines;2021-07-14

4.

Physicochemical characterization and phase I study of CMAB008, an infliximab biosimilar produced by a different expression system

;Drug Design, Development and Therapy;2019-03

5. Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera®;mAbs;2019-02-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3